Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Considerations and quality controls when analyzing cell-free tumor DNA

12 Feb 2019

Abstract excerpt

Circulating cell-free tumor DNA (ctDNA) is a promising biomarker in cancer. Ultrasensitive technologies enable detection of low (< 0.1%) mutant allele frequencies, a pre-requisite to fully utilize the potential of ctDNA in cancer diagnostics. In addition, the entire liquid biopsy workflow needs to be carefully optimized to enable reliable ctDNA analysis. Here, we discuss important considerations for ctDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations
Share to Molecular Biology Techniques and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30906693
DOI: 10.1016/j.bdq.2018.12.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Considerations and quality controls when analyzing cell-free tumor DNAPMID 30906693Read ↗

A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Semantic proximity Read ↗

Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.Semantic proximity Read ↗

Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer PatientsSemantic proximity Read ↗

Circulating tumor DNA in blood: Future genomic biomarkers for cancer detectionSemantic proximity Read ↗

Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoringSemantic proximity Read ↗

Genetic profiling of cancer with circulating tumor DNA analysis.Semantic proximity Read ↗

The feasibility of using mutation detection in ctDNA to assess tumor dynamics.Semantic proximity Read ↗

Clinical Circulating Tumor DNA Testing for Precision Oncology.Semantic proximity Read ↗

Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.Semantic proximity Read ↗

Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory settingSemantic proximity Read ↗

Cell-free DNA in cancer: current insightsSemantic proximity Read ↗

The value of cell-free DNA for molecular pathology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.